HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.

Abstract
Expression of IL-23, a heterodimeric cytokine involved in the induction of Th17 cells, is increased in human tumors. Although the endogenous IL-23 expression has been reported to promote tumor development and growth, the studies using local and systemic administration of IL-23 have shown that its application at the excessive amount induces antitumor immune responses. IL-23 is, today, considered the key driver of intestinal inflammation and its role in inflammatory responses is tissue-specific. The aim of this study was to investigate the role of circulating levels of IL-23 in patients with resected colorectal cancer (CRC) before and after chemotherapy, respect to healthy controls. Twenty-five patients were enrolled between June 2007 and January 2009, and followed through 2010. All patients underwent chemotherapy, mostly FOLFOX4. Twenty-sex and age-matched healthy donors were recruited as controls. IL-23 serum concentrations, measured by a quantitative enzyme immunoassay technique, were significantly higher in patients with resected CRC (26.02 ± 28.63 pg/ml versus 7.1 ± 6.4 pg/ml, P < 0.001) and after chemotherapy respect to controls (21.74 ± 23.82 pg/ml versus 7.17 ± 6.43 pg/ml, P < 0.001). An increase was documented also before chemotherapy (26.02 ± 28.63 pg/ml versus 21.74 ± 23.82 pg/ml, P = 0.7) but not statistically significant. This work investigated, for the first time, the role of IL-23 in CRC resection and chemotherapy, showing no correlation with the severity of disease, tumor removal, and chemotherapeutic treatment. However, other works are needed to better clarify if IL-23 could be considered a key-molecule in human CRC and a target for tumor treatment.
AuthorsV Adamo, T Franchina, P L Minciullo, E Pace, F Colonese, G R R Ricciardi, S Saitta, M Ferraro, G Spatari, S Gangemi
JournalJournal of cellular physiology (J Cell Physiol) Vol. 226 Issue 11 Pg. 3032-4 (Nov 2011) ISSN: 1097-4652 [Electronic] United States
PMID21302302 (Publication Type: Journal Article)
CopyrightCopyright © 2011 Wiley-Liss, Inc.
Chemical References
  • Antineoplastic Agents
  • Interleukin-23
  • Organoplatinum Compounds
  • Leucovorin
  • Fluorouracil
Topics
  • Adenocarcinoma (blood, drug therapy, secondary, surgery)
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Case-Control Studies
  • Colorectal Neoplasms (blood, drug therapy, pathology, surgery)
  • Female
  • Fluorouracil (therapeutic use)
  • Humans
  • Interleukin-23 (blood)
  • Leucovorin (therapeutic use)
  • Liver Neoplasms (blood, drug therapy, secondary)
  • Male
  • Middle Aged
  • Organoplatinum Compounds (therapeutic use)
  • Prognosis
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: